Inovio Pharmaceuticals, Inc. Securities Litigation

If you purchased a significant amount of shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO), you have certain options. Investors should contact us.


Lawsuit Overview

Defendant:Inovio Pharmaceuticals, Inc.
Date Filed:March 12th, 2020
Sector:Health Care
Industry:Medical/Dental Instruments
Class Start Date:February 14th, 2020
Class End Date:March 9th, 2020

According to the Complaint, Inovio Pharmaceuticals, Inc. purports to be a "biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from . . . infectious diseases."

The Complaint alleges that during the Class Period, Inovio made misleading statements about the company's development of a purported vaccine for the novel coronavirus, artificially inflating the company's share price and resulting in significant investor losses. Specifically, the Complaint alleges that Defendants capitalized on widespread COVID-19 fears by falsely claiming that Invovio had developed a vaccine for COVID-19.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Inovio Pharmaceuticals, Inc.

First Identified Complaint

Patrick McDermid, et al. v. Inovio Pharmaceuticals, Inc., et al.

Date Filed:March 12th, 2020
Class Period Start:February 14th, 2020
Class Period End:March 9th, 2020
First Identified Complaint Filings
#Document TitleFiling Date